Literature DB >> 16327360

Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment.

Lon S Schneider1.   

Abstract

This article discusses the development of drugs and treatments in the context of issues of genetics, ethnicity, and culture. A brief overview of drug development, clinical trials methods, advertising and marketing practices, and the Alzheimer's Disease Cooperative Study (ADCS) recruitment program is followed by recommendations for enhancing diversity in the development of drugs for Alzheimer's disease.

Entities:  

Mesh：

Year:  2005        PMID： 16327360     DOI： 10.1097/01.wad.0000190808.97878.b8

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN： 0893-0341            Impact factor:   2.703


  10 in total

1.  Predictors of physician referral for patient recruitment to Alzheimer disease clinical trials.

Authors:  James E Galvin; Thomas M Meuser; Linda Boise; Cathleen M Connell
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Oct-Dec       Impact factor: 2.703

Review 2.  Cognitive Training for Ethnic Minority Older Adults in the United States: A Review.

Authors:  Marian Tzuang; Jocelynn T Owusu; Adam P Spira; Marilyn S Albert; George W Rebok
Journal:  Gerontologist       Date:  2018-09-14

3.  Recruitment of a community-based cohort for research on diversity and risk of dementia.

Authors:  Ladson Hinton; Kimberly Carter; Bruce R Reed; Laurel Beckett; Esther Lara; Charles DeCarli; Dan Mungas
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

4.  Community engagement in diverse populations for Alzheimer disease prevention trials.

Authors:  Heather R Romero; Kathleen A Welsh-Bohmer; Lisa P Gwyther; Henry L Edmonds; Brenda L Plassman; Cassandra M Germain; Michelle McCart; Kathleen M Hayden; Carl Pieper; Allen D Roses
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jul-Sep       Impact factor: 2.703

5.  Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials.

Authors:  Adeline Rollin-Sillaire; Laetitia Breuilh; Julia Salleron; Stéphanie Bombois; Pascaline Cassagnaud; Vincent Deramecourt; Marie-Anne Mackowiak; Florence Pasquier
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

6.  Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

Authors:  Richard E Kennedy; Gary R Cutter; Guoqiao Wang; Lon S Schneider
Journal:  Am J Geriatr Psychiatry       Date:  2017-04-25       Impact factor: 4.105

7.  More than Tuskegee: understanding mistrust about research participation.

Authors:  Darcell P Scharff; Katherine J Mathews; Pamela Jackson; Jonathan Hoffsuemmer; Emeobong Martin; Dorothy Edwards
Journal:  J Health Care Poor Underserved       Date:  2010-08

8.  Neuropathology Studies of Dementia in US Persons other than Non-Hispanic Whites.

Authors:  My-le Nguyen; Emily Z Huie; Rachel A Whitmer; Kristen M George; Brittany N Dugger
Journal:  Free Neuropathol       Date:  2022-03-10

9.  Comparison of recruitment efforts targeted at primary care physicians versus the community at large for participation in Alzheimer disease clinical trials.

Authors:  Sarah A Carr; Roberta Davis; Diane Spencer; Marie Smart; Joanna Hudson; Stephanie Freeman; Greg E Cooper; Fred A Schmitt; William R Markesbery; Deborah Danner; Gregory A Jicha
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Apr-Jun       Impact factor: 2.703

10.  African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials.

Authors:  Yan Zhou; David Elashoff; Sarah Kremen; Edmond Teng; Jason Karlawish; Joshua D Grill
Journal:  Alzheimers Dement (N Y)       Date:  2016-10-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.